QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
NASDAQ:RAIN

Rain Oncology (RAIN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.21
$1.21
50-Day Range
$1.20
$1.24
52-Week Range
$0.82
$11.32
Volume
N/A
Average Volume
550,818 shs
Market Capitalization
$44.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RAIN stock logo

About Rain Oncology Stock (NASDAQ:RAIN)

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

RAIN Stock News Headlines

Here's how green rain works in Stardew Valley
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
See More Headlines
Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
63
Year Founded
N/A

Profitability

Net Income
$-75,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.11 per share

Miscellaneous

Free Float
30,047,000
Market Cap
$44.02 million
Optionable
Optionable
Beta
0.27
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Avanish Vellanki M.B.A. (Age 49)
    Co-Founder, CEO & Chairman
    Comp: $959.75k
  • Dr. Robert C. Doebele M.D. (Age 53)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board, President & CSO and Chief Medical Officer
    Comp: $700.56k
  • Ms. Josephine Bruce (Age 45)
    Principal Financial & Accounting officer
  • Ms. Theresa O'Connell M.S.
    Director of Corporate Development & Operations
  • Mr. Erik Atkisson (Age 52)
    General Counsel & Chief Compliance Officer
  • Ms. Charmi Turner
    Vice President of People & Culture
  • Ms. Vijaya Tirunagaru Ph.D.
    Senior VP & Head of Research
  • Dr. Nora Ku M.D.
    MD & VP of Clinical Development

RAIN Stock Analysis - Frequently Asked Questions

Should I buy or sell Rain Oncology stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings
or view top-rated stocks.

How were Rain Oncology's earnings last quarter?

Rain Oncology Inc. (NASDAQ:RAIN) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.06.

What ETFs hold Rain Oncology's stock?

ETFs with the largest weight of Rain Oncology (NASDAQ:RAIN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Horizon Kinetics Medical ETF (MEDX),

When did Rain Oncology IPO?

Rain Oncology (RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO.

Who are Rain Oncology's major shareholders?

Rain Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (3.71%), Vanguard Group Inc. (2.40%), Vanguard Group Inc. (2.40%), Deltec Asset Management LLC (1.03%), Exchange Traded Concepts LLC (0.47%) and Northern Trust Corp (0.32%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Kevin C Tang, Perceptive Advisors Llc and Value Fund L P Biotechnology.
View institutional ownership trends
.

This page (NASDAQ:RAIN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners